Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;130(5):261-269.
doi: 10.1111/apm.13215. Epub 2022 Mar 3.

Study of humoral and cellular immunity in vaccinated with mRNA-1273

Juan Francisco Gutiérrez-Bautista  1   2   3 , Miguel Ángel López-Nevot  1   3   4 , Esther Gómez-Vicente  5 , Trinidad Quesada  3 , Eva María Marín  3 , Ana Rodríguez  5 , Ana Isabel Rodríguez  5 , Javier Rodríguez-Granger  5 , Fernando Cobo  5 , Antonio Sampedro  5
Affiliations

Study of humoral and cellular immunity in vaccinated with mRNA-1273

Juan Francisco Gutiérrez-Bautista et al. APMIS. 2022 May.

Abstract

The new vaccines against SARS-CoV-2 have raised a lot of expectations about their ability to induce immunity and the duration of this. This is the case of mRNA vaccines such as Moderna's mRNA-1273. Therefore, it is necessary to study the humoral and cellular immunity generated by these vaccines. Our objectives are determining what is the normal response of antibody production, and what is the level of protective antibodies and monitoring patients in case of subsequent infection with COVID-19. We present the first results of a longitudinal study of the humoral response in 601 health workers vaccinated with Moderna. The results show a humoral immunity at 90 days after the second dose of 100%, with a strong decrease between the levels of circulating anti-S IgG antibodies between days 30 and 90 post-vaccination. Observing a steeper decline in those who had higher titles at the beginning. In addition, we present a cellular response of 86% at three months after the second dose, which is related to low humoral response.

Keywords: Moderna vaccine; SARS-CoV-2; humoral response; mRNA vaccines; mRNA-1273 vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Fig. 1
Fig. 1
(A) Distribution of the population according to the level of antibodies at 30 days post‐vaccination. (B) Distribution of the population according to the level of antibodies at 90 days post‐vaccination. (C) Anti‐S antibodies mean at 30 and 90 days post‐vaccination. * = significance, p‐value <0.05.
Fig. 2
Fig. 2
(A) Evolution of circulating antibodies in patients with levels between 0 and 500 BAU/mL at 30 days. (B) Evolution of circulating antibodies in patients with levels between 500 and 1000 BAU/mL at 30 days. (C) Evolution of circulating antibodies in patients with levels between 1000 and 3000 BAU/mL at 30 days. (D) Evolution of circulating antibodies in patients with levels between 3000 and 4000 BAU/mL at 30 days. (E) Evolution of circulating antibodies in patients with levels between 4000 and 5000 BAU/mL at 30 days. (F) Evolution of circulating antibodies in patients with levels >5000 BAU/mL at 30 days. Patients with a higher antibody level on the first antibody determination show a more pronounced decline.
See this image and copyright information in PMC

References

    1. World Health Organization . Coronavirus disease. Coronavirus Dis Situat Rep – 119 2020;2019:2633. 10.1001/jama.2020.2633 - DOI
    1. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm N‐M, et al. Vaccines for COVID‐19. Clin Exp Immunol. 2020;202:162–92. 10.1111/cei.13517 - DOI - PMC - PubMed
    1. Knoll MD, Wonodi C. Oxford‐AstraZeneca COVID‐19 vaccine efficacy. Lancet. 2021;397:72–4. 10.1016/S0140-6736(20)32623-4 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch AN, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single‐dose Ad26.COV2.S vaccine against COVID‐19. N Engl J Med. 2021;384(23):2187–201. 10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Balakrishnan VS. The arrival of Sputnik V. Lancet Infect Dis. 2020;20:1128. 10.1016/S1473-3099(20)30709-X - DOI - PMC - PubMed